文献速递贫血与红细胞疾病

心力衰竭中铁缺乏的检查与治疗:中低收入国家未满足的需求

Investigation and treatment for iron deficiency in heart failure: the unmet need in Lower and Middle Income Countries.
PubMed 文献 · Br J Haematol · 2017-05-31

综述指出,铁缺乏伴或不伴贫血影响全球超过四分之一人口,在非洲心衰患者中常见且独立关联不良预后;静脉铁可改善血清铁蛋白<100 μg/l或<300 μg/l且转铁蛋白饱和度<20%的慢性心衰患者临床结局,但中低收入国家因费用难以大规模使用静脉铁,口服铁的最佳方案尚待明确。

要点

  • 铁缺乏伴或不伴贫血影响全球超过四分之一人口,在非洲心衰患者中常见。
  • 血清铁蛋白<100 μg/l或<300 μg/l且转铁蛋白饱和度<20%的慢性心衰患者接受静脉铁后临床结局改善。
  • 中低收入国家静脉铁费用可能限制大规模使用,口服铁最佳方案尚待明确。

核心结论

  • 铁缺乏性贫血和孤立性铁缺乏是非缺血性心力衰竭的明确不良预后因素。
  • 中低收入国家心衰中铁缺乏的影响和有效管理尚未被充分描述。
  • 口服铁治疗心衰患者铁缺乏的初步数据显示对血液学和生理学变量有显著有益效果。
  • 中低收入国家静脉铁的大规模使用可能因费用受限,口服铁治疗心衰患者铁缺乏的最佳方案尚待明确。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 铁缺乏与包括非缺血性心肌病在内的多种心脏和肺部异常相关。
  • 非洲队列中心衰发生年龄较北美和欧洲更年轻,且更可能由高血压所致。
  • 非洲心衰患者中铁缺乏性贫血非常常见,铁缺乏性贫血和铁缺乏均独立关联心衰不良预后。

关键数值与推荐

  • 慢性心衰伴铁缺乏患者,血清铁蛋白<100 μg/l,或血清铁蛋白<300 μg/l且转铁蛋白饱和度<20%者,接受静脉铁后临床结局改善。
  • 铁缺乏伴或不伴贫血影响全球超过四分之一人口。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 中低收入国家心衰中铁缺乏的影响和有效管理尚未被充分描述。
  • 中低收入国家静脉铁的大规模使用可能因费用受限。
  • 口服铁治疗心衰患者铁缺乏的最佳方案尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frank iron deficiency has been associated with a wide range of cardiac and pulmonary abnormalities including non-ischaemic cardiomyopathy. Iron deficiency anaemia and isolated iron deficiency are well-defined adverse prognostic factors in non-ischaemic cardiac failure. Furthermore, iron-deficient patients in chronic heart failure with a serum ferritin of <100 μg/l or <300 μg/l with reduced transferrin saturation of <20%, who were given intravenous iron showed improved clinical outcomes. Iron deficiency with or without anaemia affects over a quarter of the world's population, but the impact of iron deficiency in heart failure and the effective management of iron deficiency in heart failure in Lower and Middle Income Countries (LMICs) is not well described. Heart failure in African cohorts occurs at a younger age than in North America and Europe and is more likely to be due to hypertension. Recent studies suggest that iron deficiency anaemia, which is very common in heart failure patients in Africa, and iron deficiency are independently associated with a poor prognosis in heart failure. Preliminary data suggest that iron deficiency in patients with heart failure can be treated with oral iron, with significant beneficial effects on haematological and physiological variables. Cost may prohibit the use of intravenous iron on a large scale in LMICs and optimal regimes to treat iron deficiency in heart failure patients with oral iron therapy remain to be defined.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Makubi A, Roberts DJ. Investigation and treatment for iron deficiency in heart failure: the unmet need in Lower and Middle Income Countries. Br J Haematol. 2017. PMID: 28568509. doi:10.1111/bjh.14650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。